Brokerages predict that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will announce earnings per share of ($1.13) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.07) and the lowest estimate coming in at ($1.31). Adamas Pharmaceuticals posted earnings per share of ($1.35) during the same quarter last year, which suggests a positive year over year growth rate of 16.3%. The business is scheduled to report its next earnings results on Thursday, May 2nd.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($4.14) per share for the current fiscal year, with EPS estimates ranging from ($4.56) to ($3.65). For the next year, analysts forecast that the business will report earnings of ($2.23) per share, with EPS estimates ranging from ($2.65) to ($1.50). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.36) by $0.30. The company had revenue of $13.32 million for the quarter, compared to the consensus estimate of $13.30 million. Adamas Pharmaceuticals had a negative return on equity of 101.46% and a negative net margin of 384.77%.

A number of analysts have commented on the company. Needham & Company LLC downgraded Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 5th. Cowen downgraded Adamas Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $30.00 to $15.00 in a research report on Tuesday, March 5th. Mizuho downgraded Adamas Pharmaceuticals from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $11.00 to $5.00 in a research report on Tuesday, March 5th. BidaskClub upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 25th. Finally, Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $23.88.

ADMS traded down $0.18 during trading on Wednesday, reaching $6.40. 277,421 shares of the stock were exchanged, compared to its average volume of 567,407. The company has a debt-to-equity ratio of 1.31, a quick ratio of 9.20 and a current ratio of 9.41. The company has a market cap of $176.50 million, a price-to-earnings ratio of -1.31 and a beta of 1.43. Adamas Pharmaceuticals has a 1 year low of $6.22 and a 1 year high of $32.90.

In other news, CEO Gregory T. Went sold 6,319 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $7.99, for a total value of $50,488.81. Following the sale, the chief executive officer now directly owns 176,291 shares in the company, valued at $1,408,565.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 8,361 shares of company stock worth $66,816 over the last 90 days. Company insiders own 24.60% of the company’s stock.

Large investors have recently modified their holdings of the company. First Mercantile Trust Co. lifted its position in shares of Adamas Pharmaceuticals by 43.2% in the fourth quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 1,740 shares in the last quarter. Advisor Group Inc. increased its stake in Adamas Pharmaceuticals by 252.0% in the fourth quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 4,510 shares during the last quarter. Pacer Advisors Inc. acquired a new position in Adamas Pharmaceuticals in the third quarter valued at $104,000. Barclays PLC increased its stake in Adamas Pharmaceuticals by 87.6% in the fourth quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock valued at $148,000 after purchasing an additional 8,118 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in Adamas Pharmaceuticals in the fourth quarter valued at $161,000. Institutional investors and hedge funds own 88.28% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

See Also: What is a Stop Order?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.